

Please type or sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet _____ of 5

Complete if Known

Application Number	09/445,517
Filing Date	December 6, 1999
First Named Inventor	Duft, et al.
Group Art Unit	1645
Examiner Name	S Devi, Ph.D.
Attorney Docket Number	030639.0044 CPA

TECH CENTER 1600/2900

JUN 12 2001

RECEIVED

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MMDDYYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
SD	AA	5,367,052		Cooper, G.J.S.	11/22/94	
SD	AB	5,175,145		Cooper, G.J.S.	12/29/92	
AC		5,124,314		Cooper, G.J.S.	6/23/92	
SD	AD	5,266,561		Cooper, G.J.S.	11/30/93	
SD	AE	5,264,372		Beaumont, K.	11/23/93	
SD	AF	5,376,638		Young, A.A.	12/27/94	
SD	AG	5,656,590		Rink, T.J.	8/12/97	
SD	AH	5,234,906		Young, A.	8/10/93	
AI		5,686,411		Gaeta	11/11/97	
SD	AJ	5,264,372		Beaumont	11/23/93	
AK		5,280,014		Cooper, G.J.S.	1/18/94	
AL		5,364,841		Garth, J.S.	11/15/94	
AM		5,739,106		Rink, T.J.	4/14/98	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³ Number ⁴	Kind Code ⁵ (if known)				
	AN	WO 9640220		Kolterman	12/19/96		
	AO	WO 9220367		Rink	11/26/92		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SD	AP	ALAM et al., "Selective Angiotensin Of Calcitonin-Induced Osteoclastic Quiescence (Q Effect) By Human Calcitonin Gene-Related Peptide-(Val ⁸ Phe ³⁷)," <i>Biochem. Biophys.</i>	

Examiner Signature SD Date Considered May 5, 2001

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

JUN 08 2001
Substitute for form 449 A/PTO

+

**PATENT INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **1** of **5**

Complete if Known

Application Number	09/445,517
Filing Date	December 6, 1999
First Named Inventor	Duft, et al.
Group Art Unit	1645
Examiner Name	S Devi, Ph.D.
Attorney Docket Number	030639.0044 CPA

TECH CENTER 1600/2900

JUN 12 2001

RECEIVED


		<u>Res. Commun.</u> , 179(1):134-139 (1991)
<i>SD</i>	AQ	ARNELO, U., et al, "Chronic infusion of islet amyloid polypeptide causes anorexia in rats," <u>Regulatory Integrative and Comparative Physiology</u> 40(6):R1654-R1659 (1996)
<i>SD</i>	AR	BEAUMONT et al., "Regulation of muscle glycogen metabolism by CGRP and amylin: CGRP receptors not involved," <u>Br. J. Pharmacol.</u> , 115(5):713-715, 1995
<i>SD</i>	AS	BRAIN et al., "Amylin Amide, Which Is Structurally Similar To Calcitonin Gene-Related Peptide (Cgrp), Stimulates Increased Blood Flow In Vivo," <u>Eur. J. Pharmacol.</u> , 183:2221 (1990)
<i>SD</i>	AT	BRAY, G.A., "Drug treatment of obesity," <u>Am J Clin Nutr</u> 55:538S-544S (1992)
<i>SD</i>	AU	BRAY, G.A. "Treatment of Obesity: A Nutrient Balance/Nutrient Partition Approach," <u>Nutrition Reviews</u> 49:33-45 (1991)
<i>SD</i>	AV	BRODERICK et al., "Human and Rat Amylin have no Effects on Insulin Secretion in Isolated Rat Pancreatic Islets," <u>Biochem. Biophys. Res. Commun.</u> , 177:932-938, 1991
<i>SD</i>	AW	BROWN et al., "The Effects of Amylin on changes in Plasma Glucose and Gastric Emptying Following an Oral Glucose Load in Conscious Dogs," <u>Diabetes</u> , 43 (Suppl 1): 172A, 1994
<i>SD</i>	AX	CHANCE et al., "Anorexia following the intrahypothalamic administration of amylin," <u>Brain Res.</u> , 539:352-354, 1991
<i>SD</i>	AY	CHANCE, W.T., et al, "Anorexia following the systemic injection of amylin," <u>Brain Res.</u> , 607:185-188 (1993)
<i>SD</i>	AZ	CHANTRY et al., "Cross-reactivity of amylin with calcitonin-gene-related peptide binding sites in rat liver and skeletal muscle membranes," <u>Biochem. J.</u> , 277:139-143, 1991
	BA	COLBURN, et al, "Pharmacokinetics and pharmacodynamics of AC137 (25,28,29 tripro-amylin, human) after intravenous bolus and infusion doses in patients with insulin-dependent diabetes," <u>J Clin. Pharmacol.</u> 36(1):13-24 (1996)
	BB	COOPER et al., "Amylin and the amylin gene: structure, function and relationship to islet amyloid and to diabetes mellitus," <u>Biochem. Biophys. Acta</u> , 1014:247-258, 1989
<i>SD</i>	BC	COOPER et al., "The Amylin Superfamily: A Novel Grouping of Biologically Active Polypeptides Related to the Insulin A-Chain," <u>Prog. Growth Factor Research</u> , 1:99-105, 1989
<i>SD</i>	BD	COOPER et al., "Amylin found in amyloid deposits in human type 2 diabetes mellitus may be a hormone that regulated glycogen metabolism in skeletal muscle," <u>Proc. Natl. Acad. Sci., USA</u> , 85:7763-7766, 1988
<i>SD</i>	BE	COOPER et al., "Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients," <u>Proc. Natl. Acad. Sci., USA</u> , 84:8628-8632, 1987

Examiner Signature	<i>SD</i>	Date Considered	May 02
--------------------	-----------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1-97A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

of

5

Complete if Known

Application Number	09/445,517
Filing Date	December 6, 1999
First Named Inventor	Duft, et al.
Group Art Unit	1645
Examiner Name	S Devi, Ph.D.
Attorney Docket Number	030639.0044 CPA

SD	BF	COOPER et al., "Amylin found in amyloid deposits in human type 2 diabetes mellitus may be a hormone that regulated glycogen metabolism in skeletal muscle," <u>Proc. Natl. Acad. Sci., USA</u> , 85:7763-7766, 1988
SD	BG	DEEMS et al., "Amylin or CGRP (8-37) Fragments Reverse Amylin-induced Inhibition of ¹⁴ C-Glycogen Accumulation," <u>Biochem. Biophys. Res. Commun.</u> , 181(1):116-120, 1991
SD	BH	FOLLETT et al., "Effect of Amylin on Insulin receptor Kinase Activity In Vivo in the Rat," <u>Clinical Research</u> , 39(1):39A (1991)
SD	BI	GAETA and RINK, "Amylin: A new hormone as a therapeutic target in diabetes mellitus and other metabolic diseases," <u>Med. Chem. Res.</u> , 3:483-490, 1994
SD	BJ	GALEAZZA et al., "Islet Amyloid Peptide (IAPP) Competes for Two Binding Sites of CGRP," <u>Peptides</u> , 12:585-591, 1991
SD	BK	GARDINER et al., "Antagonistic Effect of Human -Calcitonin Gene-Related Peptide (8-37) on Reginal Hemodynamic Actions of Rat Islet Amyloid Polypeptide in Conscious Long-Evans Rats," <u>Diabetes</u> , 40:948-951, 1991
SD	BL	GEDULIN et al., "Amylin Secretion from the Perfused Pancreas: Dissociation from Insulin and Abnormal Elevation in Insulin-Resistant Diabetic Rats," <u>Biochem. Biophys. Res. Commun.</u> , 180(1):782-789, 1991
SD	BM	GEDULIN et al., "Endogenous Amylin and Gastric Emptying in Rats: Comparison with GLP-1 and CCK-8," <u>Diabetologia</u> , 38 (suppl 1): A244 (1995)
SD	BN	GOMEZ-FOIX et al., "Anti-insulin effects of amylin and calcitonin-gene-related peptide on hepatic glycogen metabolism," <u>Biochem J.</u> , 276:607-610, 1991
SD	BO	HUANG et al., "Hyperamylinemia, Hyperinsulinemia, and Insulin Resistance in Genetically Obese LA/N-cp Rats," <u>Hypertension</u> , 19:I-101-I-109, 1991
SD	BP	JUNG and CHONG, "The Management of Obesity," <u>Clinical Endocrinology</u> 35:11-20 (1991)
SD	BQ	KODA et al., "Amylin concentrations and glucose control," <u>The Lancet</u> , 339:1179-1180, 1992
	BR	KOLTERMAN et al. "Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM," <u>Diabetologia</u> , 39:492-499, 1996.
	BS	KOLTERMAN, "Amylin and glycaemic regulation: A possible role for the human amylin analogue pramlintide," <u>Diabetic Med</u> 14(Supp 2):S35-S38 (1997)
SD	BT	KOOPMANS et al., "Amylin-induced in vivo insulin resistance in conscious rats: the liver is more sensitive to amylin than peripheral tissues," <u>Diabetologia</u> , 34:218-224, 1991
SD	BU	LEIGHTON et al., "Pancreatic amylin and calcitonin gene-related peptide cause

Examiner
Signature

SD

Date
Considered

May 6 2

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

O I P E JUN 08 2001

Please type a plus sign (+) inside this box

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1459 A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet		of	5	Attorney Docket Number	030639.0044 CPA
-------	--	----	---	------------------------	-----------------


		resistance to insulin in skeletal muscle <i>in vitro</i> ," <u>Nature</u> , 335:632-635, 1988	
57	BV	LUDVIK, et al, "Amylin: history and overview," <u>Diabet. Med.</u> 14(Supp 2)(1997)(see abstract)	
57	BW	LUPIEN et al., "No measureable effect of amylin in lipolysis in either white or brown isolated adipocytes from rats," <u>Diab. Nutr. Metab.</u> , 6(1):13-18, 1993	
	BX	LÜTZ, et al, "Reduction of food intake in rats by intraperitoneal injection of low doses of amylin," <u>Physiol. Behav.</u> , 55(5): 891-895 (1994)	
57	BY	MACDONALD et al., "Infusion of the Human Amylin Analogue, AC137 Delays gastric Emptying in Men with IDDM," <u>Diabetologia</u> 38 (suppl 1): A32 (abstract 118) 1995	
57	BZ	MOLINA et al., "Induction of Insulin Resistance In Vivo by Amylin and Calcitonin Gene-Related Peptide," <u>Diabetes</u> , 39:260-265, 1990	
57	CA	MOORE et al., "Co-Secretion of Amylin and Insulin from Cultured Islet -cells: Modulation by Nutrient Secretagogues, Islet Hormones and Hypoglycemic Agents," <u>Biochem. Biophys. Res. Commun.</u> , 179(1):1-9, 1991	
	CB	MORLEY, et al, "Amylin decreases food intake in mice," <u>Peptides</u> 12(4):865-869 (1991)	
	CC	MORLEY, et al, "Effects of amylin on appetite regulation and memory," <u>Can. J. Physiol. Pharmacol.</u> 73(7):1042-1046 (1995)	
	CD	MORLEY, et al, "Modulation of food intake by peripherally administered amylin," <u>Am. J. Physiol.</u> 267(1)(Pt 2):R178-R184 (1994)	
	CE	MOYESES, et al "Modulation of gastric emptying as a therapeutic approach to glycaemic control," <u>Diabetic Medicine</u> 13(5)(Supp 1): S34-S38 (1996)	
57	CF	NOWAK et al. "Accelerated gastric emptying in diabetic rodents: Effect of insulin treatment and pancreas transplantation," <u>J. Lab. Clin. Med.</u> , 123(1):110-6, 1994	
57	CG	PITTNER et al., "Amylin and epinephrine have no direct effect on glucose transport in isolated rat soleus muscle," <u>FEBS Letts.</u> , 365(1):98-100, 1995	
57	CH	PITTNER et al., "Molecular Physiology of Amylin," <u>J. Cell. Biochem.</u> , 55S:19-28, 1994	
57	CI	PLOURDE et al., "CGRP 8-27 Blocks the Inhibition of Gastric Emptying Induced by Intravenous Injection of -CGRP in Rats," <u>Life Sci.</u> 52:857-862, 1993	
57	CJ	RINK et al., "Structure and biology of amylin," <u>Trends In Pharmaceutical Sciences</u> (TIPS), 14:113-118, 1993	
57	CK	RODEN et al., "Effect of islet amyloid polypeptide on hepatic insulin resistance and glucose production in the isolated perfused rat liver," <u>Diabetologia</u> , 35:116-120, 1992	
	CL	ROWLAND et al. "Potential Role of Neuropeptide Ligands in the Treatment of Overeating," <u>CNS Drugs</u> , 7(6):419-420, 1997	
57	CM	STEPHENS et al., "Presence of Liver CGRP/Amylin Receptors in Only Nonparenchymal Cells and Absence of Direct Regulation of Rat Liver Glucose Metabolism by	

Examiner Signature	57	Date Considered	May 02
--------------------	----	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A (07-00)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

of 5

Complete if Known	
Application Number	09/445,517
Filing Date	December 6, 1999
First Named Inventor	Duft, et al.
Group Art Unit	1645
Examiner Name	S Devi, Ph.D.
Attorney Docket Number	030639.0044 CPA

		CGRP/Amylin," <u>Diabetes</u> , 40:395-400, 1991	
57	CN	THOMPSON, R.G., et al, "Effects of Pamlintide, an Analog of Human Amylin, on Plasma Glucose Profiles in Patients with IDDM," <u>Diabetes</u> 46:632-636 (1997)	
57	CO	WANG et al., " ⁸⁻³⁷ h-CGRP antagonizes actions of amylin on carbohydrate metabolism in vitro and in vivo," <u>FEBS Letters</u> , 291(2):195-198, 1991	
57	CP	WEISER, et al, "The pharmacologic approach to the treatment of obesity," <u>J Clin. Pharmacol.</u> 37(6):453-473 (1997)	
57	CQ	YOUNG et al., "Amylin and insulin in rat soleus muscle: dose responses for cosecreted noncompetitive antagonists," <u>Am. J. Phys.</u> , 263(2):E274-E281, 1992	
57	CR	YOUNG et al., "Effects of amylin on glucose metabolism and glycogenolysis in vivo and in vitro," <u>Am. J. Physiol.</u> , 259:E457-E461, 1990	
57	CS	YOUNG et al., "Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin," <u>Diabetologia</u> , 38(6):642-648, 1995	
57	CT	YOUNG, A.A., et al, "Preclinical Pharmacology of Pamlintide in the Rat: Comparisons with Human and Rat Amylin," <u>Drug Development Research</u> 37: 231-248 (1996)	
57	CU	YOUNG et al., "Amylin activates glycogen phosphorylase in the isolated soleus muscle of the rat," <u>FEBS Letters</u> , 281(1,2):149-151, 1991	
57	CV	YOUNG et al., " ⁸⁻³⁷ hCGRP, an amylin receptor antagonist, enhances the insulin response and perturbs the glucose response to infused arginine in anesthetized rats," <u>Mol. Cell Endocrinol.</u> , 84:R1-R5, 1992	
57	CW	ZAIDI, et al, "Amylin in Bone Conservation Current Evidence and Hypothetical Considerations," <u>Trends in Endocrinol. and Metab.</u> , 4:255-259 (1993)	
57	CX	ZHU et al., "Amylin Increases Cyclic Amp Formation in L6 Myocytes through Calcitonin Gene-Related Peptide Receptors," <u>Biochem Biophys. Res. Commun.</u> , 177(2):771-776, 1991	

Examiner Signature	57	Date Considered	May 02
--------------------	----	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside the box.

U S Patent and Trademark Office

Under the Paperwork Reduction Act of 1995, persons are required to respond to a collection of info.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

APR 23 2002 (use as many sheets as necessary)

Sheet _____ of _____

Complete if Known

Application Number	09/445,517
Filing Date	December 6, 1999
First Named Inventor	Bradford J. Duft
Group Art Unit	1645
Examiner Name	Devi, S.
Attorney Docket Number	

RECEIVED

TECH CENTER 1600/2900

COPY OF PAPERS
ORIGINALLY FILED

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		KOLTERMANN et al., "Effect Of 14 Days' Subcutaneous Administration Of The Human Amylin Analogue, Pramlintide (AC137) On An Intravenous Insulin Challenge And Response To A Standard Liquid Meal In Patients With IDDM," <u>Diabetologia</u> , 39(4):492-9 (1996)	
SD		KONG et al., "Infusion Of Pramlintide, A Human Amylin Analogue, Delays Gastric Emptying In Men With IDDM," <u>Diabetologia</u> , 40(1):82-88 (1997)	
SD		KONG et al., "The Effect Of Single Doses Of Pramlintide On Gastric Emptying Of Two Meals In Men With IDDM," <u>Diabetologia</u> , 41(5):577-83 (1998)	
SD		NYHOLM et al., "Acute Effects Of The Human Amylin Analog AC137 On Basal And Insulin-Stimulated Euglycemic And Hypoglycemic Fuel Metabolism In Patients With Insulin-Dependent Diabetes Mellitus," <u>J. Clin. Endocrinol. Metab.</u> , 81(3):1083-89 (1996)	
SD		SCHMITZ et al., "Effects Of Amylin And The Arnylin Agonist Pramlintide On Glucose Metabolism," <u>Diabetic Med.</u> , 14(2):S19-S23 (1997)	
SD		THOMPSON et al., "Effects Of 4 Weeks' Administration Of Pramlintide, A Human Amylin Analogue, On Glycaemia Control In Patients With IDDM: Effects On Plasma Glucose Profiles And Serum Fructosamine Concentrations," <u>Diabetologia</u> , 40(11):1278-1285 (1997)	
SD		THOMPSON et al., "Pramlintide: A Human Amylin Analogue Reduced Postprandial Plasma Glucose, Insulin, And C-Peptide Concentrations In Patients With Type 2 Diabetes," <u>Diabetic Med.</u> , 14(7):547-55 (1997)	
SD		WANG et al., "Influence Of Islet Amyloid Polypeptide And The 8-37 Fragment of Islet Amyloid Polypeptide on Insulin Release From Perifused Rat Islets," <u>Diabetes</u> , 42(2):330-5 (1993)	

Examiner Signature	SD	Date Considered	May 02
--------------------	----	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.